Unity Biotechnology upgraded by Roth Capital with a new price target
$UBX
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $2.00 | Buy → Neutral | H.C. Wainwright |
| 5/16/2025 | $6.00 → $1.00 | Outperform → Neutral | Mizuho |
| 8/22/2024 | $8.00 | Buy | Rodman & Renshaw |
| 11/16/2023 | $2.00 → $4.00 | Neutral → Outperform | Wedbush |
| 1/4/2022 | $4.00 | Neutral → Buy | Roth Capital |
| 1/4/2022 | Neutral → Buy | ROTH Capital | |
| 11/10/2021 | $5.00 → $7.00 | Neutral → Buy | Mizuho |
| 6/28/2021 | Sell → Buy | Citigroup |